UPCOMING SESSIONS in ET
Tue, Sep 8, 2026
5:00 – 6:00 AM Bangkok
Your First Mayo Clinic Evaluation: What to Expect and How to Prepare Cecelia Hernandez Click Here To Register
UPCOMING SESSIONS in ET
Tue, Sep 8, 2026 · 5:00 – 6:00 AM Bangkok
Your First Mayo Clinic Evaluation: What to Expect and How to Prepare
Cecelia Hernandez
Click Here To Register
View all sessions

News

finance yahoo
Jun 12, 2026
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
Alnylam Pharmaceuticals ALNY is a commercial-stage company that currently markets four drugs. The company first received regulatory approval in 2018 for…
Read more
PubMed
Jun 12, 2026
Early timepoint 99mTc-DPD whole body scintigraphy and quantitative SPECT/CT imaging for diagnosis of cardiac ATTR amyloidosis
AbstractBackground: Cardiac transthyretin amyloidosis (ATTR-CM) is a progressive myocardial disease ultimately leading to heart failure. Standard diagnostic workup…
Read more
Cureus
Jun 11, 2026
Cholestatic Jaundice Without Hepatomegaly as the Initial Manifestation of Hepatic Amyloid Light-Chain (AL) Amyloidosis: A Case of Rapid Multiorgan Failure
AbstractSystemic amyloid light-chain (AL) amyloidosis is a rare plasma cell disorder characterized by extracellular deposition of misfolded immunoglobulin light…
Read more
amyloidosis
Jun 11, 2026
DKSH Partners BridgeBio to Expand Access to Innovative ATTR-CM Therapy Across Asia-Pacific
(Singapore, 11.06.2026)DKSH has entered into a strategic distribution partnership with biotechnology company BridgeBio to support the regulatory evaluation and…
Read more
PubMed
Jun 11, 2026
First Japanese Case of Hereditary Transthyretin Amyloid Cardiomyopathy with an Ile68Leu Variant: A Case Report
AbstractTransthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly recognized because of improved diagnostic modalities and disease-modifying therapy. We report…
Read more
ResearchGate
Jun 11, 2026
Vutrisiran in transthyretin amyloid cardiomyopathy: a structured review of the HELIOS-B trial and its secondary analyses
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy caused by myocardial deposition of misfolded transthyretin, leading to…
Read more
ResearchGate
Jun 11, 2026
Timeliness of Transthyretin Cardiac Amyloidosis Diagnosis in the Medicare Population
Abstract and FiguresImportance Timely diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) is critical for early treatment to reduce morbidity and mortality,…
Read more
ClinicalTrials.gov
Jun 11, 2026
Single-arm, Multi-center Study Evaluating the Acceptance and Feasibility of a Digital Remote Monitoring Tool Configured for Patients With ATTR-CM: ACO-Monitor (ACO-MONITOR)
Study OverviewBrief SummaryTransthyretin amyloid cardiomyopathy (ATTR-CM) is a heart condition caused by a protein called transthyretin (TTR) building up as amyloid…
Read more
finance yahoo
Jun 11, 2026
DKSH Enters Strategic Distribution Partnership with BridgeBio to Support Regulatory Evaluation and Potential Patient Access to Transthyretin Stabilizer for ATTR-CM in Selected Asia Pacific Markets
SINGAPORE, June 11, 2026 /PRNewswire/ -- DKSH entered a strategic distribution partnership with BridgeBio to support regulatory evaluation and potential patient…
Read more
amyloidosis
Jun 11, 2026
Bone hormone levels signal heart disease severity in ATTR-CM: Study
Higher blood levels of fibroblast growth factor 23 (FGF23) — a bone-derived hormone — are associated with higher levels of established markers of heart damage and…
Read more
Subscribe to